Understanding immune responses to influenza vaccination in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study assesses the cellular and humoral immune responses elicited by seasonal influenza vaccination in healthy adults. It aims to enroll up to 100 participants of varying birth years to explore how age-specific differences influence immune responses. The researchers hypothesize that individuals born in different years will exhibit distinct antibody and cellular responses to the vaccine due to prior exposures to influenza viruses. The study will measure these immune responses before and after vaccination to gain insights into vaccine effectiveness across different age groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for all study visits
3. Aged 18 years and older
4. In good health based on self-reported medical conditions via an online survey

Exclusion Criteria:

1. Known allergic reactions to components of the study vaccine
2. Known latex allergy
3. History of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines
4. History of GBS within 6 weeks of receipt of a previous influenza vaccine
5. Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months
6. Treatment with immunoglobulin or another blood product within the 3 months prior to enrollment in this study
7. Active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy ("active" is defined as having received treatment within the past 5 years)
8. Long-term (greater than 2 weeks) usage of oral or parenteral steroids, or high-dose inhaled steroids
9. Administration of an influenza vaccine within 2 months prior to enrollment
10. Known acute or chronic medical condition that, in the opinion of the investigator or appropriate sub-investigator, would render vaccination unsafe or would interfere with the evaluation of responses
11. Participation in a study that involves an experimental agent or having received an experimental agent (other than a COVID-19 vaccine) within 1 month prior to enrollment or expecting to receive another experimental agent during the study period
12. Intends to donate blood during the study period
13. Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
14. Pregnancy
15. Known human immunodeficiency virus, hepatitis B, or hepatitis C infection
16. Any condition that the principal investigator believes may interfere with successful completion of the study

Where it's running

• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Scott Hensley, PhD
• Email: hensley@pennmedicine.upenn.edu
• Phone: 215-573-3756

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Influenza vaccine based on mRNA in adults 18-64

  A vaccine made with mRNA is being tested in adults 18 to 64 to see if it triggers a good immune response and is safe.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Glendale, Arizona and 11 other locations · NCT07851246

• Baloxavir for preventing flu after exposure in household contacts

  A single dose of baloxavir marboxil is being tested to see if it prevents symptomatic, lab-confirmed influenza in people who live with someone who has flu symptoms.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Guangzhou, Guangdong and 7 other locations · NCT07827599

• Influenza vaccine study for adults 65 and older

  A vaccine trial tests an investigational mRNA flu shot against a licensed flu vaccine in adults 65+ to see if it better prevents flu during the season.

  Recruiting at 163 sites Phase 3 GlaxoSmithKline · Anniston, Alabama and 162 other locations · NCT07805707

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Testing a new quadrivalent influenza vaccine for safety and effectiveness

  This study is testing a new flu vaccine to see if it's safe and effective for adults aged 18 and older.

  Recruiting Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Shijiazhuang, Hebei · NCT06824519

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.